Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome
Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome
About this item
Full title
Author / Creator
Publisher
England: eLife Sciences Publications Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: eLife Sciences Publications Ltd
Subjects
More information
Scope and Contents
Contents
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are anti-hyperglycemic agents that prevent glucose reabsorption in proximal tubular cells. SGLT2i improves renal outcomes in both diabetic and non-diabetic patients, indicating it may have beneficial effects beyond glycemic control. Here, we demonstrate that SGLT2i affects energy metabolism and pod...
Alternative Titles
Full title
Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_8d37cf2ae9d140ee9fdc28b97b8e5e79
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8d37cf2ae9d140ee9fdc28b97b8e5e79
Other Identifiers
ISSN
2050-084X
E-ISSN
2050-084X
DOI
10.7554/eLife.83353
